<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00028691</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069120</org_study_id>
    <secondary_id>CKVO-2001-01</secondary_id>
    <secondary_id>HOVON-47NHL</secondary_id>
    <secondary_id>EU-20131</secondary_id>
    <secondary_id>HOVON-CKTO-2001-01</secondary_id>
    <secondary_id>EORTC-20013</secondary_id>
    <nct_id>NCT00028691</nct_id>
  </id_info>
  <brief_title>Chlorambucil Compared With Radiation Therapy in Treating Patients With Previously Untreated Stage III or Stage IV Follicular Lymphoma</brief_title>
  <official_title>Chlorambucil Versus 2x2 Gy Involved Field Radiotherapy in Stage III/IV Previously Untreated Follicular Lymphoma Patients. A Prospective, Randomized Phase III Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Commissie Voor Klinisch Toegepast Onderzoek</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer
      cells. It is not yet known if chlorambucil is more effective than radiation therapy in
      treating follicular lymphoma.

      PURPOSE: Randomized phase III trial to compare the effectiveness of chlorambucil with that of
      radiation therapy in treating patients who have stage III or stage IV follicular lymphoma
      that has not been previously treated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the effect of chlorambucil vs involved-field radiotherapy on progression-free
           survival of patients with previously untreated stage III or IV follicular lymphoma.

        -  Compare the complete and partial remission rates and overall survival of patients
           treated with these regimens.

        -  Compare the toxicity of these regimens in these patients.

        -  Compare the quality of life of patients treated with these regimens.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
      participating center. Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive oral chlorambucil on days 1-5. Treatment repeats every 4 weeks
           for 6-8 courses in the absence of disease progression or unacceptable toxicity.

        -  Arm II: Patients undergo radiotherapy on days 1 and 3 (and days 15 and 17 for split
           course).

      Quality of life is assessed at baseline, prior to course 3, 6, and 8 (arm I), and then at 4-6
      weeks after study.

      Patients are followed at 4-6 weeks, 3-4 months (arm I), 3 months and 6 months (arm II), 11,
      12, 15, 18, and 21 months, and then every 6 months thereafter.

      PROJECTED ACCRUAL: A total of 444 patients (222 per treatment arm) will be accrued for this
      study within 4 years.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2002</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chlorambucil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of follicular lymphoma

               -  Stage III or IV disease

               -  Grades I, II, or III

               -  Previously untreated disease

          -  Nodal and extranodal sites

          -  Bidimensionally measurable disease by physical examination or diagnostic imaging

          -  No CNS or orbital non-Hodgkin's lymphoma localization

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over (for patients at EORTC centers)

          -  65 and over (for patients at HOVON centers)

        Performance status:

          -  WHO 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  WBC at least 4,000/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hemoglobin at least 6.0 g/dL

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Cardiovascular:

          -  No severe cardiac disease that would preclude study treatment

        Pulmonary:

          -  No severe pulmonary disease that would preclude study treatment

        Other:

          -  HIV negative

          -  No severe neurologic, psychiatric, or metabolic disease that would preclude study
             treatment

          -  No other prior malignancy except basal cell skin cancer or carcinoma in situ of the
             cervix

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Not specified

        Endocrine therapy:

          -  No concurrent systemic corticosteroids, including dexamethasone for nausea and
             vomiting palliation (inhalation and topical corticosteroids allowed)

        Radiotherapy:

          -  No concurrent elective radiotherapy to an adjacent negative lymph node

        Surgery:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rick L. M. Haas, MD</last_name>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>T. Girinsky, MD</last_name>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Middelheim</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek Hospital</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <zip>7500 KA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 EZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastro Clinic</name>
      <address>
        <city>Heerlen</city>
        <zip>NL-6401 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiotherapeutisch Instituut Limburg-Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>NL-6229 ET</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daniel Den Hoed Cancer Center at Erasmus University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Haas RL, Girinsky T. HOVON 47/EORTC 20013: chlorambucil vs 2x2 Gy involved field radiotherapy in stage III/IV previously untreated follicular lymphoma patients. Ann Hematol. 2003 Jul;82(7):458-62. Epub 2003 May 20.</citation>
    <PMID>12756499</PMID>
  </results_reference>
  <verification_date>January 2002</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorambucil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

